Considerations for setting occupational exposure limits for novel pharmaceutical modalities

In order to develop new and effective medicines, pharmaceutical companies must be modality agnostic. As science reveals an enhanced understanding of biological processes, new therapeutic modalities are becoming important in developing breakthrough therapies to treat both rare and common diseases. As...

Descripción completa

Detalles Bibliográficos
Autores principales: Graham, Jessica C., Hillegass, Jedd, Schulze, Gene
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2020
Materias:
Contemporary Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7605856/
https://www.ncbi.nlm.nih.gov/pubmed/33144077
http://dx.doi.org/10.1016/j.yrtph.2020.104813

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7605856/
https://www.ncbi.nlm.nih.gov/pubmed/33144077
http://dx.doi.org/10.1016/j.yrtph.2020.104813

Ejemplares similares